Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
MRI exams are crucial for investigating fetal abnormalities, but past concerns have been expressed about whether the modality could affect intrauterine growth.
In addition to more traditional presentations, this year's meeting will also include "Rapid Fire" sessions designed to pack a lot of late-breaking data into a relatively small amount of time.
The findings, based on data from more than 800 TAVR patients, suggest that skipping OAC medications for a small amount of time could make a big impact.
“No clear recommendation currently exists in U.S. or European guidelines for performing PCI in addition to TAVR,” researchers wrote. The group hoped its study could provide some clarity.
According to new MODULAR ATP data, the leadless system was associated with a high success rate and few complications. Boston Scientific plans on seeking FDA approval in 2025.